Minervax ApS develops vaccines against Group B streptococcus (GBS) infections
MinervaX has raised €178M across 5 funding rounds from 16 investors, most recently a round in Oct 2023. Based in Hellerup, Denmark; founded 2010; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2023-10-11 | Other | €54M | Adjuvant Capital,EQT Life Sciences,Industrifonden,LF Investment,Novo Holdings,OrbiMed+5 more | View deal → |
| 2022-12-16 | Debt | €50M | European Investment Bank | View deal → |
| 2022-12-16 | Other | €22M | Adjuvant Capital,Industrifonden,LF Investment,Pureos Bioventures,Repair Impact Fund,Sanofi Ventures+3 more | View deal → |
| 2020-12-15 | Series B | €47M | — | View deal → |
| 2019-01-01 | Other | €4.4M | Repair Impact Fund,Sunstone Capital | View deal → |
